| pubmed-article:16796788 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0206454 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0879427 | lld:lifeskim |
| pubmed-article:16796788 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
| pubmed-article:16796788 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16796788 | pubmed:dateCreated | 2006-6-26 | lld:pubmed |
| pubmed-article:16796788 | pubmed:abstractText | Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC: mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epiderman growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients with increased severity significantly correlated with improved medium overall survival (OS). Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer. | lld:pubmed |
| pubmed-article:16796788 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16796788 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16796788 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16796788 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16796788 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16796788 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16796788 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16796788 | pubmed:month | May | lld:pubmed |
| pubmed-article:16796788 | pubmed:issn | 1533-0028 | lld:pubmed |
| pubmed-article:16796788 | pubmed:author | pubmed-author:GrotheyAxelA | lld:pubmed |
| pubmed-article:16796788 | pubmed:author | pubmed-author:GibsonTara... | lld:pubmed |
| pubmed-article:16796788 | pubmed:author | pubmed-author:RanganathanAa... | lld:pubmed |
| pubmed-article:16796788 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16796788 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:16796788 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16796788 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16796788 | pubmed:pagination | 29-31 | lld:pubmed |
| pubmed-article:16796788 | pubmed:dateRevised | 2008-5-30 | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:meshHeading | pubmed-meshheading:16796788... | lld:pubmed |
| pubmed-article:16796788 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16796788 | pubmed:articleTitle | Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. | lld:pubmed |
| pubmed-article:16796788 | pubmed:affiliation | CIG Medical Group, LP, Dallas, TX, USA. | lld:pubmed |
| pubmed-article:16796788 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16796788 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:16796788 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16796788 | lld:pubmed |
